SynthesisJournal of cosmetic dermatology2025
Therapeutic Benefits of Topical Omega-3 Polyunsaturated Fatty Acids in Skin Diseases and Cosmetics: An Updated Systematic Review.
Synthesis in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic Benefits of Topical Omega-3 Polyunsaturated Fatty Acids in Skin Diseases and Cosmetics: An Updated Systematic Review.Journal of cosmetic dermatology · 2025Pooled it
- Effectiveness of omega-3 poly unsaturated fatty acids on the treatment of gingival hyperpigmentation: a randomized controlled clinical trial.BMC oral health · 2026Trial
- The Gut-Brain-Skin Axis: Systemic Effects of Functional Ingredients in Healthy Skin Aging.International journal of molecular sciences · 2026Review
- A Novel Urea Complexation Method for Enrichment of n-3 Polyunsaturated Fatty Acids.Molecules (Basel, Switzerland) · 2026Article
- Cricket Oil-Based Sunscreen Systems: Formulation Design, Ultraviolet Protection Performance, and Preclinical Safety Evaluation.Pharmaceutics · 2026Article
- Effectiveness of Eicosapentaenoic and Docosahexaenoic Acid Supplementation for Reducing Uremic Pruritus: A Meta-Analysis of Randomized Controlled Trials.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Skin examination in extreme conditions.Acta biochimica Polonica · 2026Review
- Causal Effect of Plasma Fatty Acid Profiles on Psoriasis Risk: Genetic Evidence from a Mendelian Randomization Study.Psoriasis (Auckland, N.Z.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral supplementation with omega-3 polyunsaturated fatty acids (ω-3 PUFAs) has shown beneficial effects in some dermatologic diseases (i.e., atopic dermatitis, acne, psoriasis, burns), but the actual effect of local application of ω-3 PUFAs for improving skin health is still under investigation.
aimsThis paper systematically reviewed the current articles regarding the use of topical ω-3 PUFAs in the treatment of skin diseases to evaluate its efficacy and safety.
methodsThe review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) recommendations. Studies in which ω-3 PUFAs were administered as oral treatments, those with a reduced or unknown ω-3 PUFAs composition, and those using with skin fish grafts were excluded.
resultsIn skin models of psoriasis, wounds, dermatitis, and melanoma, topical ω-3 PUFAs showed an overall beneficial effect associated with the anti-inflammatory properties of these compounds. Furthermore, none of the studies reported cases of skin irritation, cytotoxicity, or any adverse events.
conclusionsThe increasing number of studies conducted on topical treatments with ω-3 PUFAs and the existing evidence suggest that ω-3 PUFAs could be a promising option as an adjuvant or complementary treatment in managing several dermatological conditions. However, there is still a lack of consensus about the optimal dosage, molecules, or delivery methods of ω-3 PUFAs; consequently, more clinical studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.